CREBBP and prostate carcinoma: In the cancer field, FT-7051, which is an oral, potent, and selective inhibitor of CBP/EP300 bromodomain with activity in preclinical prostate cancer models, is currently in a phase 1 open-label study to examine the safety, PK/PD, and preliminary anti-tumor activity in castration-resistant prostate cancer patients (NCT04575766) [108].